BRIEF published on 05/21/2025 at 08:05, 1 year 3 months ago TME Pharma Enhances Financial Outlook with €1.7M Bond Commitments Strategic Partnerships Bond Issuance Clinical Programs Financial Visibility Cost Structure
PRESS RELEASE published on 05/21/2025 at 08:00, 1 year 3 months ago Informations privilégiées / Autres communiqués TME Pharma, société de biotechnologie spécialisée en thérapies contre le cancer, prolonge sa visibilité financière jusqu'en mai 2026 via une émission d'obligations aux investisseurs professionnels Investisseurs Obligations Cancer Visibilité Financière TME Pharma
PRESS RELEASE published on 05/21/2025 at 08:00, 1 year 3 months ago Inside Information / Other news releases TME Pharma extends financial visibility to May 2026 by securing €1.7M financing through regular bonds with attached warrants. CEO and board show strong commitment to company's success Clinical Programs TME Pharma Financial Visibility Regular Bonds Private Warrants
BRIEF published on 04/10/2025 at 19:05, 1 year 5 months ago TME Pharma renforce son contrat de liquidité avec Invest Securities Contrat De Liquidité INVEST SECURITIES Marchés Financiers Oncologie TME Pharma
BRIEF published on 04/10/2025 at 19:05, 1 year 5 months ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 1 year 5 months ago Informations privilégiées / Autres communiqués TME Pharma augmente les ressources allouées au contrat de liquidité confié à Invest Securities pour renforcer la trésorerie. Détails des ressources disponibles après l'augmentation Contrat De Liquidité INVEST SECURITIES Trésorerie Ressources TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 1 year 5 months ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
BRIEF published on 02/17/2025 at 08:05, 1 year 6 months ago TME Pharma présente sa feuille de route stratégique et ses initiatives pour 2025 Biotechnologie Partenariats Stratégiques Thérapie Contre Le Cancer Découverte De Médicaments NOX-A12
BRIEF published on 02/17/2025 at 08:05, 1 year 6 months ago TME Pharma Outlines 2025 Strategic Roadmap and Initiatives Strategic Partnerships Biotechnology Drug Discovery Cancer Therapy NOX-A12
PRESS RELEASE published on 02/17/2025 at 08:00, 1 year 6 months ago Inside Information / Other news releases TME Pharma CEO Aram Mangasarian outlines key initiatives and milestones for 2025, including strategic partnerships, NOX-A12 clinical development, AI-driven drug discovery, and financial updates Strategic Partnerships Clinical Development CEO Message TME Pharma 2025 Initiatives
Published on 09/12/2026 at 02:35, 14 hours 6 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 17 hours 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 18 hours 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 19 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 23 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 9 hours 11 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 18 hours 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 18 hours 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 20 hours 56 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 22 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 21 hours ago Availability of the 2026 Interim Financial Report
